Efficacy and safety of patients immunization with chronic obstructive pulmonary disease with monoclonal antibodies
Background. Chronic obstructive pulmonary disease (COPD) is characterized by a high level of morbidity and mortality and is associated with significant social and economic damage to the health system and society. COPD and COVID-19 have many potentially negative relationships that can lead to worse o...
Main Authors: | Vladimir N. Antonov, Galina L. Ignatova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2023-04-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/346667/118473 |
Similar Items
-
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients
by: Andrea Lombardi, et al.
Published: (2023-05-01) -
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study
by: Mohammed Kamal Nassar, et al.
Published: (2023-12-01) -
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
by: Daniele Focosi, et al.
Published: (2022-09-01) -
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
by: Francesco Marchesi, et al.
Published: (2023-04-01) -
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
by: Daria S. Fomina, et al.
Published: (2023-10-01)